Next Article in Journal
Idiopathic Pulmonary Hemosiderosis Mimicking Iron Deficiency Anemia: A Delayed Diagnosis?
Previous Article in Journal
Thalidomide for the Treatment of Gastrointestinal Bleeding Due to Angiodysplasia in a Patient with Glanzmann’s Thrombasthenia
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Hematology Reports
Volume 9
Issue 2
10.4081/hr.2017.7114
hematolrep-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Hematology Reports is published by MDPI from Volume 14 Issue 1 (2022). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with PAGEPress.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Brief Report

Bridging-to-Transplant with Azacitidine for Myelodysplastic Syndrome and Acute Myeloid Leukemia, Reduces the Incidence of Acute Graft-versus-Host Disease

by
Koichi Murakami
,
Hironori Ueno
,
Takashi Okabe
,
Toshiya Kagoo
,
Saigen Boku
,
Takahiro Yano
and
Akihiro Yokoyama
*
Division of Hematology, Department of Internal Medicine, National Hospital Organization Tokyo Medical Center, Tokyo, Japan
*
Author to whom correspondence should be addressed.
Hematol. Rep. 2017, 9(2), 7114; https://doi.org/10.4081/hr.2017.7114
Submission received: 5 March 2017 / Revised: 24 April 2017 / Accepted: 9 May 2017 / Published: 15 June 2017

Abstract

Allogeneic stem cell transplantation (allo-SCT) is the only curative option for myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Azacitidine (AZA) has a good toxicity profile compared with intensive chemotherapy and can be considered a pre-transplant regimen in elderly patients and in patients with comorbidities. To investigate the impact of pre-transplant AZA on patient outcome after allo-SCT, we conducted a retrospective analysis of AZA pre-treatment followed by allo-SCT in patients with high-risk MDS and AML. Twenty patients who were divided into two groups according to AZA treatment given prior to allo-SCT (AZA vs non- AZA group, 10 each). Overall survival, event-free survival and incidence of chronic graft-versus-host disease (GVHD) were not significantly different between the two groups. The overall incidence of grade II to IV acute GVHD in the AZA group was significantly lower than that in the non-AZA group (p = 0.004). Bridging to transplant with AZA should be considered as an immunomodulator and effective treatment strategy for patients with MDS and AML.
Keywords: azacitidine; bridging to transplan; immunomodulater; acute GVHD azacitidine; bridging to transplan; immunomodulater; acute GVHD

Share and Cite

MDPI and ACS Style

Murakami, K.; Ueno, H.; Okabe, T.; Kagoo, T.; Boku, S.; Yano, T.; Yokoyama, A. Bridging-to-Transplant with Azacitidine for Myelodysplastic Syndrome and Acute Myeloid Leukemia, Reduces the Incidence of Acute Graft-versus-Host Disease. Hematol. Rep. 2017, 9, 7114. https://doi.org/10.4081/hr.2017.7114

AMA Style

Murakami K, Ueno H, Okabe T, Kagoo T, Boku S, Yano T, Yokoyama A. Bridging-to-Transplant with Azacitidine for Myelodysplastic Syndrome and Acute Myeloid Leukemia, Reduces the Incidence of Acute Graft-versus-Host Disease. Hematology Reports. 2017; 9(2):7114. https://doi.org/10.4081/hr.2017.7114

Chicago/Turabian Style

Murakami, Koichi, Hironori Ueno, Takashi Okabe, Toshiya Kagoo, Saigen Boku, Takahiro Yano, and Akihiro Yokoyama. 2017. "Bridging-to-Transplant with Azacitidine for Myelodysplastic Syndrome and Acute Myeloid Leukemia, Reduces the Incidence of Acute Graft-versus-Host Disease" Hematology Reports 9, no. 2: 7114. https://doi.org/10.4081/hr.2017.7114

APA Style

Murakami, K., Ueno, H., Okabe, T., Kagoo, T., Boku, S., Yano, T., & Yokoyama, A. (2017). Bridging-to-Transplant with Azacitidine for Myelodysplastic Syndrome and Acute Myeloid Leukemia, Reduces the Incidence of Acute Graft-versus-Host Disease. Hematology Reports, 9(2), 7114. https://doi.org/10.4081/hr.2017.7114

Article Metrics

Back to TopTop